vs
Side-by-side financial comparison of ClearPoint Neuro, Inc. (CLPT) and Ellomay Capital Ltd. (ELLO). Click either name above to swap in a different company.
Ellomay Capital Ltd. is the larger business by last-quarter revenue ($20.1M vs $10.4M, roughly 1.9× ClearPoint Neuro, Inc.).
ClearPoint Neuro, Inc. is a medical technology firm specializing in precision neurology solutions. It develops and commercializes intraoperative navigation, targeting and delivery systems for minimally invasive brain surgeries, neurological disorder treatments, and CNS therapy development for global clinical and biopharmaceutical partners.
Ellomay Capital Ltd is a renewable energy enterprise focused on the development, ownership, and operation of clean power assets. Its portfolio includes solar photovoltaic projects, onshore wind farms, and pumped storage hydroelectric facilities, with core operations across Israel and key European markets, delivering low-carbon energy to both commercial and residential end consumers.
CLPT vs ELLO — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.4M | $20.1M |
| Net Profit | — | — |
| Gross Margin | 61.5% | 12.1% |
| Operating Margin | -67.7% | -11.8% |
| Net Margin | — | — |
| Revenue YoY | 34.0% | — |
| Net Profit YoY | — | — |
| EPS (diluted) | $-0.26 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $10.4M | — | ||
| Q3 25 | $8.9M | — | ||
| Q2 25 | $9.2M | $20.1M | ||
| Q1 25 | $8.5M | — | ||
| Q4 24 | $7.8M | — | ||
| Q3 24 | $8.1M | — | ||
| Q2 24 | $7.9M | $19.5M | ||
| Q1 24 | $7.6M | — |
| Q4 25 | — | — | ||
| Q3 25 | $-5.9M | — | ||
| Q2 25 | $-5.8M | — | ||
| Q1 25 | $-6.0M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-5.0M | — | ||
| Q2 24 | $-4.4M | — | ||
| Q1 24 | $-4.1M | — |
| Q4 25 | 61.5% | — | ||
| Q3 25 | 63.2% | — | ||
| Q2 25 | 60.3% | 12.1% | ||
| Q1 25 | 60.5% | — | ||
| Q4 24 | 61.3% | — | ||
| Q3 24 | 59.7% | — | ||
| Q2 24 | 63.5% | 8.7% | ||
| Q1 24 | 59.2% | — |
| Q4 25 | -67.7% | — | ||
| Q3 25 | -59.5% | — | ||
| Q2 25 | -61.6% | -11.8% | ||
| Q1 25 | -72.6% | — | ||
| Q4 24 | -72.5% | — | ||
| Q3 24 | -63.5% | — | ||
| Q2 24 | -60.1% | -9.3% | ||
| Q1 24 | -55.2% | — |
| Q4 25 | — | — | ||
| Q3 25 | -66.5% | — | ||
| Q2 25 | -63.3% | — | ||
| Q1 25 | -71.0% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -61.2% | — | ||
| Q2 24 | -56.1% | — | ||
| Q1 24 | -54.3% | — |
| Q4 25 | $-0.26 | — | ||
| Q3 25 | $-0.21 | — | ||
| Q2 25 | $-0.21 | — | ||
| Q1 25 | $-0.22 | — | ||
| Q4 24 | $-0.20 | — | ||
| Q3 24 | $-0.18 | — | ||
| Q2 24 | $-0.16 | — | ||
| Q1 24 | $-0.16 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $45.9M | $54.5M |
| Total DebtLower is stronger | $49.1M | — |
| Stockholders' EquityBook value | $28.0M | $171.5M |
| Total Assets | $97.7M | $855.5M |
| Debt / EquityLower = less leverage | 1.75× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.9M | — | ||
| Q3 25 | $38.2M | — | ||
| Q2 25 | $41.5M | $54.5M | ||
| Q1 25 | $12.4M | — | ||
| Q4 24 | $20.1M | — | ||
| Q3 24 | $21.6M | — | ||
| Q2 24 | $32.8M | $59.9M | ||
| Q1 24 | $35.4M | — |
| Q4 25 | $49.1M | — | ||
| Q3 25 | $29.2M | — | ||
| Q2 25 | $28.8M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $10.0M | — | ||
| Q1 24 | $10.0M | — |
| Q4 25 | $28.0M | — | ||
| Q3 25 | $15.9M | — | ||
| Q2 25 | $19.7M | $171.5M | ||
| Q1 25 | $20.0M | — | ||
| Q4 24 | $25.4M | — | ||
| Q3 24 | $29.0M | — | ||
| Q2 24 | $32.1M | $136.3M | ||
| Q1 24 | $34.6M | — |
| Q4 25 | $97.7M | — | ||
| Q3 25 | $60.4M | — | ||
| Q2 25 | $62.9M | $855.5M | ||
| Q1 25 | $30.1M | — | ||
| Q4 24 | $39.2M | — | ||
| Q3 24 | $40.2M | — | ||
| Q2 24 | $52.6M | $678.9M | ||
| Q1 24 | $53.6M | — |
| Q4 25 | 1.75× | — | ||
| Q3 25 | 1.84× | — | ||
| Q2 25 | 1.46× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.31× | — | ||
| Q1 24 | 0.29× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-12.1M | $5.1K |
| Free Cash FlowOCF − Capex | $-12.1M | — |
| FCF MarginFCF / Revenue | -116.5% | — |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-24.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-12.1M | — | ||
| Q3 25 | $-3.1M | — | ||
| Q2 25 | $-2.6M | $5.1K | ||
| Q1 25 | $-6.2M | — | ||
| Q4 24 | $-1.2M | — | ||
| Q3 24 | $-1.2M | — | ||
| Q2 24 | $-2.7M | $468.0K | ||
| Q1 24 | $-3.8M | — |
| Q4 25 | $-12.1M | — | ||
| Q3 25 | $-3.3M | — | ||
| Q2 25 | $-2.6M | — | ||
| Q1 25 | $-6.4M | — | ||
| Q4 24 | $-1.5M | — | ||
| Q3 24 | $-1.2M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -116.5% | — | ||
| Q3 25 | -37.5% | — | ||
| Q2 25 | -28.7% | — | ||
| Q1 25 | -74.9% | — | ||
| Q4 24 | -19.4% | — | ||
| Q3 24 | -14.9% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 0.5% | — | ||
| Q3 25 | 2.2% | — | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | 3.4% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.0% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLPT
| Neurosurgery Navigation And Therapy Disposable Products | $4.7M | 45% |
| Biologics And Drug Delivery Services And License Fees | $2.8M | 27% |
| Biologics And Drug Delivery Disposable Products | $2.4M | 23% |
| Other | $502.0K | 5% |
ELLO
Segment breakdown not available.
